Eletriptan for acute migraine headaches in adults

Derry, Sheena; Moore, R Andrew; McQuay, Henry J

doi:10.1002/14651858.cd008490

Cited by 2 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The putative mechanisms of eletriptan therapeutic action in migraine are multiple: (i) it has a vasoconstrictive action on dilated meningeal blood vessels; (ii) in perivascular trigeminal sensory neurons it inhibits the release of vasoactive neuropeptides and (iii) reduces the pain signal transmission in the trigeminal dorsal horn [Derry et al 2010]. The vasoconstrictive action has been demonstrated in vitro for isolated canine and human arteries, and the vasoconstriction of isolated human meningeal artery with a potency similar to that of sumatriptan (EC 50 = 50 nm) has been demonstrated.…”

Section: Pharmacodynamicsmentioning

confidence: 99%

“…Eletriptan is orally administered in tablets of 20 mg and 40 mg, with a maximum daily dose of 80 mg [Derry et al 2010]. The absorption, central nervous system penetration and volume of distribution are higher than those of the other triptans, given the greater lipophilicity of eletriptan [+0.5 (log D at pH 7.4)] [Sandrini et al 2009].…”

Section: Pharmacokineticsmentioning

confidence: 99%

Section: Eletriptan Biochemical and Pharmacological Featuresmentioning

confidence: 99%

“…Eletriptan is orally administered in tablets of 20 mg and 40 mg, with a maximum daily dose of 80 mg [Derry et al . 2010].…”

Section: Eletriptan Biochemical and Pharmacological Featuresmentioning

confidence: 99%

See 3 more Smart Citations

Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response

Capi

Curto

Lionetto

et al. 2016

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Migraine is a multifactorial, neurological and disabling disorder, also characterized by several autonomic symptoms. Triptans, selective serotonin 5-HT 1B/1D agonists, are the first-line treatment option for moderate-to-severe headache attacks. In this paper, we review the recent data on eletriptan clinical efficacy, safety, and tolerability, and potential clinically relevant interactions with other drugs. Among triptans, eletriptan shows a consistent and significant clinical efficacy and a good tolerability profile in the treatment of migraine, especially for patients with cardiovascular risk factors without coronary artery disease. It shows the most favorable clinical response, together with sumatriptan injections, zolmitriptan and rizatriptan. Additionally, eletriptan shows the most complex pharmacokinetic/dynamic profile compared with the other triptans. It is metabolized primarily by the CYP3A4 hepatic enzyme and therefore the concomitant administration of CYP3A4-potent inhibitors should be carefully evaluated. A relatively low risk of serotonin syndrome is given by the coadministration with serotoninergic drugs. No clinically relevant interaction has been found with drugs used for migraine prophylactic treatment or other acute drugs, with the exception of ergot derivatives that should not be co-administered with eletriptan.

show abstract

Section: Pharmacodynamicsmentioning

confidence: 99%

Section: Pharmacokineticsmentioning

confidence: 99%

Section: Eletriptan Biochemical and Pharmacological Featuresmentioning

confidence: 99%

“…Eletriptan is orally administered in tablets of 20 mg and 40 mg, with a maximum daily dose of 80 mg [Derry et al . 2010].…”

Section: Eletriptan Biochemical and Pharmacological Featuresmentioning

confidence: 99%

See 2 more Smart Citations

Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response

Capi

Curto

Lionetto

et al. 2016

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

A novel LC-MS method development and validation for the determination of phenyl vinyl sulfone in eletriptan hydrobromide

2021

View full text Add to dashboard Cite

Background The aim of the present method is to develop and validate a specific, sensitive, precise, and accurate liquid chromatography-mass spectrometry (LC-MS) method for the estimation of the phenyl vinyl sulfone in the eletriptan hydrobromide. The effective separation of the phenyl vinyl sulfone was achieved by the Symmetry C18 (50 × 4.6 mm, 3.5 μm) column and a mobile phase composition of 0.1%v/v ammonia buffer to methanol (5:95 v/v), using 0.45 ml/min flow rate and 20 μl of injection volume, with methanol used as diluent. The phenyl vinyl sulfone was monitored on atomic pressure chemical ionization mode mass spectrometer with positive polarity mode. Results The retention time of phenyl vinyl sulfone was found at 2.13 min. The limit of detection (LOD) and limit of quantification (LOQ) were observed at 1.43 ppm and 4.77 ppm concentration respectively; the linear range was found in the concentration ranges from 4.77 to 27.00 ppm with regression coefficient of 0.9990 and accuracy in the range of 97.50–102.10%. The percentage relative standard deviation (% RSD) for six replicates said to be injections were less than 10%. Conclusion The proposed method was validated successfully as per ICH guidelines. Hence, this is employed for the determination of phenyl vinyl sulfone in the eletriptan hydrobromide.

show abstract

Eletriptan for acute migraine headaches in adults

Abstract: This is the protocol for a review and there is no abstract. The objectives are as follows: The objective of the review will be to determine the efficacy and tolerability of eletriptan compared to placebo and other active interventions in the treatment of acute migraine headaches in adults.

Cited by 2 publications

References 25 publications

Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response

Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response

A novel LC-MS method development and validation for the determination of phenyl vinyl sulfone in eletriptan hydrobromide

Contact Info

Product

Resources

About